ɬ﷬

News

Do I need a COVID-19 booster shot?

Six questions answered on how to stay protected
William Petri
By William Petri
July 17, 2021

The increasing prevalence of is raising questions about how well protected those who’ve already had their COVID-19 shots are against evolving forms of the SARS-CoV-2 virus. Here, of the University of Virginia answers some common questions about COVID-19 booster shots.

Booster-445x559.jpg
,
A booster shot may be necessary to maintain COVID-19 immunity.

1. What is a booster shot?

Boosters are an extra dose of a vaccine given to maintain vaccine-induced protection against a disease. They are commonly used to bolster many vaccines because immunity can . For example, the needs a booster every year, and the every 10 years.

Boosters are often identical to the original vaccine. In some cases, however, the booster shot has been modified to enhance protection against new viral variants. The , most notably, requires an annual booster because the flu virus changes so rapidly.

2. Do I need to get a COVID-19 booster?

Not yet. As of early July 2021, none of the U.S. government authorities is recommending a booster. This includes the Centers for Disease Control and Prevention, the Food and Drug Administration and the Advisory Committee on Immunization Practices to the CDC.

3. Why aren’t booster shots recommended yet?

While vaccine-induced immunity may not last forever, it is not clear when a booster will be needed.

Encouragingly, all of the currently authorized COVID-19 vaccines induce a robust immune memory against the coronavirus. The vaccine teaches your immune system’s to produce antibodies when you’re exposed to the virus. Researchers have detected high levels of memory B cells in the lymph nodes of people who received the Pfizer vaccine for after they got the shot.

Studies also suggest that authorized COVID-19 vaccines are continuing to offer protection even against . Among one study’s participants, the Johnson & Johnson vaccine had 14 days and 28 days post shot, respectively, at warding off severe disease from the beta variant. And a preliminary study that has not been peer-reviewed found the Pfizer vaccine to be against the delta variant.

The other source of long-lasting antibody responses against the coronavirus is cells called that reside in bone marrow. These cells continuously produce antibodies and do not require boosting to maintain their activity. Fortunately, plasmablasts have been detected in the bone marrow of for up to 11 months, indicating some degree of long-lasting immune memory.

Booster shots remind your immune system of the pathogen it’s been immunized against.

4. How will I know if I need a booster?

You may need to wait for an outbreak in people who have been vaccinated. Researchers are still figuring out the best way to measure the strength of someone’s vaccine-induced immunity. The COVID-19 vaccines have been so effective that there are not many failures to test.

The best candidate to measure are certain antibodies the vaccine induces the immune system to make. They recognize the that allows the coronavirus to enter and infect cells. Evidence supporting the importance of anti-spike antibodies includes a study showing that the somewhat more effective mRNA vaccines like Pfizer and Moderna generate than the adenovirus vector vaccines like Johnson & Johnson and AstraZeneca. In a that has not yet been peer-reviewed, anti-spike antibody levels were lower in people who caught COVID-19 after they were vaccinated with the Oxford–AstraZeneca vaccine.

Medical workers would love to be able to give patients a blood test that would tell them how well protected they are or aren’t against COVID-19. That would be a clear indication as to whether a booster shot is needed.

But until researchers know for sure how to measure vaccine-induced immunity, the next indication that boosters may be needed are breakthrough infections in older adults who have already been vaccinated. People over the age of 80 make after vaccination, so their immunity may wane sooner than that of the general population. The elderly would also most likely be the that evade the protection current vaccines provide.

5. I’m immunocompromised – should I worry?

Boosters may be necessary for immunocompromised people. In one study, 39 of 40 kidney transplant recipients and a third of dialysis patients . Another study identified 20 patients with on medications that suppress the immune system who also did not have detectable antibodies. Both of these studies were done after patients received the full vaccine dose.

Boosters have been shown to help in these cases. In one study, one-third of who had a suboptimal response to two doses of the Pfizer or Moderna vaccines were able to develop an antibody response with a third dose.

Those who are immunocompromised may wonder if the vaccine they received is successfully generating immunity in their body. A preliminary study that has not yet been peer-reviewed did find that a the vaccines trigger may be helpful in determining whether the vaccine worked. But for now, the antibody tests to assess immunity.

6. Does my booster need to match my first shots?

Likely not. Recent research has shown that mRNA vaccines, like Pfizer and Moderna, can be mixed with adenovirus-based vaccines like AstraZeneca with .

This article is republished from under a Creative Commons license. Read the .

The Conversation

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
William Petri
William Petri

William Petri is a professor of  medicine and microbiology at the University of Virginia who specializes in infectious diseases.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.